{"@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.patentleaderboard.com/"}, {"@type": "ListItem", "position": 2, "name": "Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics", "item": "https://www.patentleaderboard.com/patent/7727525"}]}
Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics

Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics

US Patent 7727525 · Granted Jun 1, 2010

Estimated economic value: $5,176,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antigen binding constructs to CD82025
Antigen binding constructs to CD42025
Extension sequences for diabodies2022
Antigen binding constructs to target molecules2022
J591 minibodies and cys-diabodies for targeting human prostate specific membrane2021
Antigen binding constructs to CD32021
Antigen binding constructs to CD82019
Fully human antibodies and fragments recognizing human c-Met2019
Antigen binding constructs to CD82019
Antigen binding constructs to CD32019
Covalent disulfide-linked diabodies and uses thereof2017
Covalent disulfide-linked diabodies and uses thereof2017